Biological PCR Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Reagents and Consumables), By End Use (Diagnostic Laboratories and Molecular Testing Laboratories), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 13.51 Billion
CAGR (2026-2031)	7.42%
Fastest Growing Segment	Reagents
Largest Market	North America
Market Size (2031)	USD 20.76 Billion

Market Overview

The Global Biological PCR Technology Market will grow from USD 13.51 Billion in 2025 to USD 20.76 Billion by 2031 at a 7.42% CAGR. Biological PCR technology is a core molecular diagnostic method utilized to amplify specific DNA segments, allowing for the detection and analysis of genetic material in clinical, research, and forensic settings. The market is primarily driven by the rising prevalence of infectious diseases and the increasing requirement for genetic testing in oncology and personalized medicine. According to the World Health Organization, in 2024, approximately 8.3 million people globally were reported as newly diagnosed with tuberculosis, a statistic that underscores the critical demand for accurate molecular diagnostic solutions to manage high-burden diseases.

However, the market faces a significant challenge regarding the substantial implementation costs associated with advanced PCR instrumentation and the necessity for specialized technical expertise. These financial and operational barriers can restrict the adoption of complex PCR systems in resource-limited environments, potentially impeding market expansion in developing regions where the need for diagnostic testing is often substantial.

Key Market Drivers

The expansion of point-of-care (POC) testing and portable diagnostic devices is fundamentally reshaping the market by decentralizing molecular diagnostics and enabling rapid decision-making outside traditional laboratories. This shift is powered by innovations that integrate complex PCR workflows into compact, user-friendly platforms, significantly reducing turnaround times for critical infectious disease management. A prime example of this trend is the growing regulatory approval of syndromic panels that allow non-laboratory professionals to conduct testing in near-patient settings. According to bioMérieux, June 2024, in the 'bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini' press release, the company secured approval for a multiplex PCR test capable of detecting five common viral and bacterial pathogens in approximately 15 minutes, directly addressing the need for decentralized urgent care solutions.

Simultaneously, the surge in clinical applications for infectious disease management serves as a primary catalyst for market growth, necessitated by the increasing global burden of these conditions. As the prevalence of pathogens rises, healthcare systems are prioritizing high-sensitivity molecular techniques to ensure early detection and targeted treatment strategies. According to the World Health Organization, December 2024, in the 'World malaria report 2024', there were an estimated 263 million malaria cases globally in 2023, an increase of about 11 million cases compared to the previous year, highlighting the urgent requirement for robust diagnostic surveillance. To meet such escalating clinical demands, major industry players are scaling their operational capacities and realizing significant commercial gains. According to Roche, January 2025, in the 'Roche reports strong 2024 results' statement, the company's Diagnostics Division reported sales of CHF 14.3 billion, with the base business growing by 8% due to high demand for immunodiagnostic and molecular solutions.

Download Free Sample Report

Key Market Challenges

The Global Biological PCR Technology Market faces a substantial hurdle in the form of high implementation costs for advanced instrumentation and the critical need for specialized technical expertise. These financial and operational barriers significantly restrict the adoption of complex PCR systems, particularly in resource-limited settings and developing regions. Laboratories operating with constrained budgets often struggle to justify the initial capital expenditure required for sophisticated amplification platforms, while the ongoing expenses related to maintenance and reagents further strain financial resources. Consequently, this economic pressure limits the market’s reach, preventing the widespread deployment of molecular diagnostic capabilities where they are often most needed for managing infectious disease burdens.

This financial strain is further exacerbated by a tightening reimbursement landscape, which reduces the available capital laboratories need to invest in such high-cost technologies. According to the American Clinical Laboratory Association, in 2024, clinical laboratories faced scheduled Medicare reimbursement reductions of up to 15% for approximately 800 diagnostic tests. Such reductions in operational revenue directly diminish the capacity of healthcare facilities to fund the acquisition of expensive PCR systems and recruit the skilled personnel necessary to operate them, thereby hampering the overall growth potential of the market.

Key Market Trends

The proliferation of PCR applications in liquid biopsy and oncology is advancing the market, particularly for Minimal Residual Disease (MRD) monitoring and non-invasive cancer detection. This trend shifts the diagnostic focus from invasive tissue biopsies to blood-based testing, enabling the precise identification of circulating tumor DNA (ctDNA) for recurrence prediction. The escalating clinical adoption of these PCR-integrated workflows is evidenced by the substantial volume growth in oncology testing services, which directly stimulates demand for high-sensitivity amplification technologies. According to Natera, November 2025, in the 'Natera Reports Third Quarter 2025 Financial Results' press release, the company performed approximately 211,000 oncology tests in the third quarter of 2025, an increase of 53.9% compared to the prior year, underscoring the rapid market penetration of these molecular solutions.

Simultaneously, the expansion of PCR testing into food safety and agricultural sectors is broadening the technology's utility beyond clinical healthcare. Industrial laboratories are increasingly replacing traditional culture-based methods with rapid molecular assays to ensure supply chain integrity and meet stringent regulatory standards for pathogen detection. This shift toward industrial applications is driving robust demand for specialized reagents and automated platforms designed to deliver faster time-to-result in high-throughput settings. According to bioMérieux, March 2025, in the '2024 Financial Results' report, the company's Industrial Applications division achieved sales growth of close to 9% for the full year, a performance primarily fueled by double-digit increases in reagent sales within the food safety segment.

Segmental Insights

The Reagents segment currently represents the fastest-growing category within the Global Biological PCR Technology Market, primarily driven by the high recurrence of consumption inherent in diagnostic and research workflows. Unlike instruments that constitute one-time capital investments, reagents are continuously utilized for every reaction, creating a steady stream of demand. This expansion is further accelerated by the rising prevalence of infectious diseases and genetic disorders, which necessitates frequent clinical testing. Additionally, the consistent authorization of new diagnostic kits by regulatory authorities such as the US FDA supports market adoption, thereby ensuring sustained momentum for this segment.

Regional Insights

North America maintains a dominant position in the global biological PCR technology market, driven by a robust healthcare infrastructure and extensive research activities. The region benefits significantly from continuous government funding for genomic studies, particularly through initiatives supported by the National Institutes of Health. Additionally, the strong presence of major biotechnology corporations facilitates widespread product availability and development. The U.S. Food and Drug Administration plays a crucial role by providing clear regulatory frameworks that streamline product approvals, further encouraging market expansion. These factors collectively support North America's sustained leadership in this sector.

Recent Developments

• In September 2024, Roche announced the launch of the cobas Respiratory flex test, a diagnostic tool utilizing its proprietary Temperature-Activated Generation of Signal (TAGS) technology. This breakthrough allowed for the simultaneous detection of up to 15 pathogens using a single polymerase chain reaction (PCR) test on high-throughput systems. The technology overcame previous multiplexing limitations by combining color, temperature, and data processing to differentiate results. This development significantly advanced the Global Biological PCR Technology Market by enabling syndromic panel testing on routine molecular diagnostic analyzers, thereby improving laboratory efficiency and facilitating faster, more comprehensive patient diagnoses for respiratory illnesses.
• In September 2024, Qiagen N.V. expanded its presence in the Global Biological PCR Technology Market with the launch of the QIAcuityDx Digital PCR System. This platform was designed to bring the precision of digital PCR into clinical diagnostics, offering absolute quantification of DNA and RNA for applications such as oncology and rare disease monitoring. The system received IVDR certification in Europe and 510(k) exemption in the United States, streamlining its adoption in clinical laboratories. By integrating partitioning, thermocycling, and imaging into a single workflow, the company aimed to enhance diagnostic accuracy and support the development of non-invasive liquid biopsy testing.
• In April 2024, Bio-Rad Laboratories, Inc. entered into a strategic collaboration with Oncocyte Corporation to commercialize transplant monitoring products utilizing Droplet Digital PCR (ddPCR) technology. This partnership focused on developing assays that detect donor-derived cell-free DNA in the bloodstream, a sensitive biomarker for assessing organ health and potential rejection. By leveraging Bio-Rad’s QX600 ddPCR System, the initiative aimed to provide a non-invasive, highly precise alternative to traditional biopsy methods. This agreement strengthened the Global Biological PCR Technology Market by expanding the clinical utility of digital PCR in post-transplant care and facilitating the global distribution of advanced monitoring solutions.
• In March 2024, Cepheid received clearance from the U.S. Food and Drug Administration for the Xpert Xpress GBS, a molecular diagnostic test designed for the intrapartum detection of Group B Streptococcus. This next-generation polymerase chain reaction (PCR) test incorporated dual targets within highly conserved regions of the bacterial genome to enhance sensitivity and strain coverage. The launch addressed the need for rapid and accurate results during labor to prevent early-onset sepsis in newborns. This advancement contributed to the Global Biological PCR Technology Market by providing healthcare professionals with a reliable, near-patient PCR testing solution that supports timely clinical decision-making in maternal care.

Key Market Players

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN GmbH
• Takara Bio Inc.
• Merck KGaA
• Bioneer Corporation
• Illumina, Inc.
• Promega Corporation
• Eppendorf SE

By Product Type	By End Use	By Region
Reagents and Consumables	Diagnostic Laboratories and Molecular Testing Laboratories	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Biological PCR Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Biological PCR Technology Market, By Product Type:

• Reagents and Consumables

• Biological PCR Technology Market, By End Use:

• Diagnostic Laboratories and Molecular Testing Laboratories

• Biological PCR Technology Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE